Meta-analysis confirms benefits and safety of precision medicine
Meta-analysis confirms benefits and safety of precision medicine
Chemoresistance and residual disease promoted by DNMT3A R882 in AML
TAT 2016: Targeted anticancer therapies
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma
Exciting update on the Repurposing Drugs in Oncology (ReDO) project
Overview of innovation in Hodgkin's lymphoma
EHA 2015: Expert opinions on new treatment standard in multiple myeloma
Advances in the treatment and management of CLL
PM1183 plus doxorubicin shows interesting activity in small cell lung cancer
Expert overview on the recent developments in mantle cell lymphoma
Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer
Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma